Article
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
The Journal of experimental medicine - 3 May 2021
Stuani Lucille, Sabatier Marie, Saland Estelle, Cognet Guillaume, Poupin Nathalie, Bosc Claudie, Castelli Florence A, Gales Lara, Turtoi Evgenia, Montersino Camille, Farge Thomas, Boet Emeline, Broin Nicolas, Larrue Clément, Baran Natalia, Cissé Madi Y, Conti Marc, Loric Sylvain, Kaoma Tony, Hucteau Alexis, Zavoriti Aliki, Sahal Ambrine, Mouchel Pierre-Luc, Gotanègre Mathilde, Cassan Cédric, Fernando Laurent, Wang Feng, Hosseini Mohsen, Chu-Van Emeline, Le Cam Laurent, Carroll Martin, Selak Mary A, Vey Norbert, Castellano Rémy, Fenaille François, Turtoi Andrei, Cazals Guillaume, Bories Pierre, Gibon Yves, Nicolay Brandon, Ronseaux Sébastien, Marszalek Joseph R, Takahashi Koichi, DiNardo Courtney D, Konopleva Marina, Pancaldi Véra, Collette Yves, Bellvert Floriant, Jourdan Fabien, Linares Laetitia K, Récher Christian, Portais Jean-Charles, Sarry Jean-Emmanuel
Abstract excerpt
Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias, and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell lines, PDXs, and patients with acute myeloid leukemia (AML) harboring an IDH mutation displayed an enhanced mitochondrial oxidative metabolism. Along with an increase in TCA cycle intermediates, this AML-specific metabolic...
Topics
Join the communities discussing this publication.